These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1974005)

  • 1. Ropinirole without levodopa in Parkinson's disease.
    Vidailhet MJ; Bonnet AM; Belal S; Dubois B; Marle C; Agid Y
    Lancet; 1990 Aug; 336(8710):316-7. PubMed ID: 1974005
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of Parkinson's disease with novel dopamine D2 agonist SK&F 101468.
    Kapoon R; Pirtosek Z; Frankel JP; Stern GM; Lees AJ; Bottomley JM; Haran NS
    Lancet; 1989 Jun; 1(8652):1445-6. PubMed ID: 2567448
    [No Abstract]   [Full Text] [Related]  

  • 3. Ropinirole (SK and F 101468) in the treatment of Parkinson's disease.
    Kleedorfer B; Stern GM; Lees AJ; Bottomley JM; Sree-Haran N
    J Neurol Neurosurg Psychiatry; 1991 Oct; 54(10):938. PubMed ID: 1683897
    [No Abstract]   [Full Text] [Related]  

  • 4. Augmentation of artistic productivity in Parkinson's disease.
    Walker RH; Warwick R; Cercy SP
    Mov Disord; 2006 Feb; 21(2):285-6. PubMed ID: 16261619
    [No Abstract]   [Full Text] [Related]  

  • 5. Ropinirole therapy for Parkinson's disease.
    Pahwa R; Lyons KE; Hauser RA
    Expert Rev Neurother; 2004 Jul; 4(4):581-8. PubMed ID: 15853577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
    Inzelberg R; Schechtman E; Nisipeanu P
    Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Deleu D; Hanssens Y
    Neurology; 2006 May; 66(10):1611-2; author reply 1611-2. PubMed ID: 16721952
    [No Abstract]   [Full Text] [Related]  

  • 8. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.
    Rascol O; Brooks DJ; Korczyn AD; De Deyn PP; Clarke CE; Lang AE
    N Engl J Med; 2000 May; 342(20):1484-91. PubMed ID: 10816186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Nutt JG
    Neurology; 2006 May; 66(10):1611-2; author reply 1611-2. PubMed ID: 16717244
    [No Abstract]   [Full Text] [Related]  

  • 10. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.
    Rascol O; Brooks DJ; Brunt ER; Korczyn AD; Poewe WH; Stocchi F
    Mov Disord; 1998 Jan; 13(1):39-45. PubMed ID: 9452324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study.
    Mizuno Y; Abe T; Hasegawa K; Kuno S; Kondo T; Yamamoto M; Nakashima M; Kanazawa I;
    Mov Disord; 2007 Oct; 22(13):1860-5. PubMed ID: 17618525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH; Ha JH; Cho IS; Lee MC
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
    Whone AL; Watts RL; Stoessl AJ; Davis M; Reske S; Nahmias C; Lang AE; Rascol O; Ribeiro MJ; Remy P; Poewe WH; Hauser RA; Brooks DJ;
    Ann Neurol; 2003 Jul; 54(1):93-101. PubMed ID: 12838524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ropinirole does not affect plasma arginine vasopressin levels in patients with advanced Parkinson's disease.
    Arai M
    Neuro Endocrinol Lett; 2012; 33(7):680-3. PubMed ID: 23391874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ropinirole: new preparation. Wait for more convincing data.
    Prescrire Int; 1998 Apr; 7(34):36-8. PubMed ID: 10183378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors influencing dopaminergic therapy of Parkinson's disease.
    Horowski R
    Funct Neurol; 1988; 3(4):459-70. PubMed ID: 2907501
    [No Abstract]   [Full Text] [Related]  

  • 17. [Parlodel in early combination with levodopa in the treatment of Parkinson disease. Comparison of 2 dosage forms].
    Goulley F; Wolmark Y; Bourdeix I; Chaumet-Riffaud PD
    Therapie; 1993; 48(3):233-8. PubMed ID: 7908147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ropinirole: a review of its use in the management of Parkinson's disease.
    Matheson AJ; Spencer CM
    Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose therapy with ropinirole in patients with Parkinson's disease.
    Müngersdorf M; Sommer U; Sommer M; Reichmann H
    J Neural Transm (Vienna); 2001; 108(11):1309-17. PubMed ID: 11768629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nasogastric and intravenous infusions of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's disease.
    Coleman RJ; Quinn NP; Traub M; Marsden CD
    J Neurol Neurosurg Psychiatry; 1990 Feb; 53(2):102-5. PubMed ID: 1968963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.